Parp Inhibitor – Savior for Ovarian Cancer Patients
Cancer is the most bloodcurdling disease. As soon as a person is diagnosed with any type of cancer, he or she feels like dying. Ovarian cancer is the most challenging disease found among women and is the most common cancer that causes death among women. For the first time after much research and study, a cure has been found for ovarian cancer.
The doctors have discovered a cure for the treatment of ovarian cancer in the form of a parp inhibitor. Parp inhibitors are also known as "olaparib” in medical language. An Australian medical team has identified a hopeful treatment for the most common ovarian cancer.
The clinical team examined whether the new treatment found (i.e. olaparib) can avert the growth of ovarian cancer in the patient’s body or not. It was also tested that after successful completion of chemotherapy whether olaprib can help inhibiting reformation of ovarian cancer or not. The research head Clare Scott in Melbourne said the study can be most beneficial for treating ovarian cancer.
According to Scott, the parp inhibitor helps in delaying the growth of ovarian cancer among the patients. Scott also said that like other cancers ovarian cancer is hard to detect in its initial stage. Moreover, it is also common that ovarian cancer once treated can again reoccur in the body.
Ovarian cancer is treated with surgery followed by chemotherapy so that the cancer and dead cells are removed from the patient’s body. In most of the cases chemotherapy helps in shrinking the cancer cells and patients are treated well. There are also cases where the patient’s body does not accept chemotherapy and leads to regeneration of the ovarian cancer.
The researchers have also found that the ovarian cancer patients who are treated with chemotherapy have a reduction of the cancer cells. The remission of cancer cells remains till an average of eight months. The patients who have received the treatment of chemotherapy in combination with parp inhibitors has slower growth of cells rather than those who have received an inactive panacea.